Search
Close this search box.

A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response

Print Friendly, PDF & Email

Gambardella G, Viscido G, Tumaini B, Isacchi A, Bosotti R, di Bernardo D
Nat Commun (2022), 13(1), 1714

A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours
Nerviano MS Logo

Follow Us on

Nerviano Medical Sciences S.r.l. 

Viale Luigi Pasteur 10
20014 Nerviano (MI)
Italy

Share Capital: € 1,200,000.00
fully paid-in

Company subject to the management and coordination of NMS Group S.p.A.

Copyright © 2022 Nerviano Medical Sciences S.r.l
Website by Axxiem

Share this page

Facebook
Twitter
LinkedIn
Email
svg.e-font-icon-svg {display:none!important} .elementor-button-icon {display:none!important} .show-more, .show-more2 {display:none!important} img.pf-large-image.pf-primary-img.flex-width.pf-size-full.blockImage { display: none!important; }